{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:12:02Z","timestamp":1791817922825,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10067-023-06751-0","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T07:01:59Z","timestamp":1696575719000},"page":"3289-3297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-1569","authenticated-orcid":false,"given":"Abhilasha","family":"Manwatkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5369-7062","authenticated-orcid":false,"given":"Shivraj","family":"Padiyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-917X","authenticated-orcid":false,"given":"Aswin","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-0827","authenticated-orcid":false,"given":"Avanish","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-7475","authenticated-orcid":false,"given":"Sathish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5764-1373","authenticated-orcid":false,"given":"Bijesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-8456","authenticated-orcid":false,"given":"John Antony Jude","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-4954","authenticated-orcid":false,"given":"John Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9857-2271","authenticated-orcid":false,"given":"John","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"6751_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ncl.2014.04.007","volume":"32","author":"MM Dimachkie","year":"2014","unstructured":"Dimachkie MM, Barohn RJ, Amato A (2014) Idiopathic inflammatory myopathies. Neurol Clin 32:595\u2013628","journal-title":"Neurol Clin"},{"key":"6751_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8\u201323","journal-title":"J Intern Med"},{"key":"6751_CR3","doi-asserted-by":"publisher","unstructured":"You H et al (2022) Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China. Rheumatology keac450. https:\/\/doi.org\/10.1093\/rheumatology\/keac450","DOI":"10.1093\/rheumatology\/keac450"},{"key":"6751_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.semarthrit.2020.10.014","volume":"51","author":"L Gupta","year":"2021","unstructured":"Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R (2021) Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin Arthritis Rheum 51:113\u2013120","journal-title":"Semin Arthritis Rheum"},{"key":"6751_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clim.2018.11.008","volume":"198","author":"L Zhong","year":"2019","unstructured":"Zhong L, Yu Z, Song H (2019) Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: a meta-analysis of 20 cohorts. Clin Immunol Orlando Fla 198:11\u201318","journal-title":"Clin Immunol Orlando Fla"},{"key":"6751_CR6","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J et al (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res 69:1771\u20131776","journal-title":"Arthritis Care Res"},{"key":"6751_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 92:223\u2013243","journal-title":"Medicine"},{"key":"6751_CR8","doi-asserted-by":"publisher","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","volume":"3","author":"M Bottai","year":"2017","unstructured":"Bottai M et al (2017) EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 3:e000507","journal-title":"RMD Open"},{"key":"6751_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"6751_CR10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1007\/s00415-019-09266-4","volume":"266","author":"F Montagnese","year":"2019","unstructured":"Montagnese F, Baba\u010di\u0107 H, Eichhorn P, Schoser B (2019) Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study. J Neurol 266:1358\u20131366","journal-title":"J Neurol"},{"key":"6751_CR11","doi-asserted-by":"crossref","unstructured":"Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, Tincani A, Ross SJ, Chan JY, Pauley BA, Chan EK, Satoh M (2012) Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis. Arthritis Res Ther 14(2):R97","DOI":"10.1186\/ar3822"},{"key":"6751_CR12","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s10067-021-05590-1","volume":"40","author":"AM Nair","year":"2021","unstructured":"Nair AM et al (2021) Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort. Clin Rheumatol 40:2805\u20132819","journal-title":"Clin Rheumatol"},{"issue":"3","key":"6751_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/injr.injr_139_22","volume":"18","author":"S Padiyar","year":"2023","unstructured":"Padiyar S, Nair AM, Yadav B, Manikuppam P, Jha A, Manwatkar AA et al (2023) Clinical characteristics, therapeutics, and treatment outcomes of adult patients with anti-melanoma differentiation-associated gene 5 dermatomyositis: a single-center experience from South India. Indian J Rheumatol 18(3):205\u2013211","journal-title":"Indian J Rheumatol"},{"key":"6751_CR14","doi-asserted-by":"publisher","first-page":"672008","DOI":"10.3389\/fimmu.2021.672008","volume":"12","author":"A Aguilar-Vazquez","year":"2021","unstructured":"Aguilar-Vazquez A et al (2021) Geographical latitude remains as an important factor for the prevalence of some myositis autoantibodies: a systematic review. Front Immunol 12:672008","journal-title":"Front Immunol"},{"key":"6751_CR15","doi-asserted-by":"publisher","unstructured":"Ichimura Y et al (2021) Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatol Oxf Engl keab518. https:\/\/doi.org\/10.1093\/rheumatology\/keab518","DOI":"10.1093\/rheumatology\/keab518"},{"key":"6751_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF (2017) Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res 69:1909\u20131914","journal-title":"Arthritis Care Res"},{"key":"6751_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:710\u2013713","journal-title":"Ann Rheum Dis"},{"key":"6751_CR18","doi-asserted-by":"publisher","unstructured":"Loarce-Martos J et al (2021) Clinical characteristics of juvenile idiopathic inflammatory myopathy and comparison with adult patients: analysis from a multicentric cohort in Spain. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. https:\/\/doi.org\/10.1097\/RHU.0000000000001696","DOI":"10.1097\/RHU.0000000000001696"},{"key":"6751_CR19","doi-asserted-by":"publisher","first-page":"1155839","DOI":"10.3389\/fmed.2023.1155839","volume":"10","author":"CS Pinotti","year":"2023","unstructured":"Pinotti CS, Cannon L, Dvergsten JA, Wu EY (2023) Calcinosis in juvenile dermatomyositis: updates on pathogenesis and treatment. Front Med 10:1155839","journal-title":"Front Med"},{"key":"6751_CR20","doi-asserted-by":"publisher","first-page":"101768","DOI":"10.1016\/j.berh.2022.101768","volume":"36","author":"S Davuluri","year":"2022","unstructured":"Davuluri S, Duvvuri B, Lood C, Faghihi-Kashani S, Chung L (2022) Calcinosis in dermatomyositis: origins and possible therapeutic avenues. Best Pract Res Clin Rheumatol 36:101768","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06751-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T07:18:17Z","timestamp":1699687097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06751-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6751"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06751-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This retrospective study was approved by the Institutional Review Board-IRB Min. No. 14171 dated 28.07.2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}